ALT In order to improve the prognosis of people with ‘treatment resistant depression’, it is important to consider alternative pathways and augmentations to currently available treatments. For instance, a previous randomised controlled trial (RCT), the Tavistock Adult Depression Study (TADS; Fonagy et al., 2015) found that treatment-as-usual (TAU) combined with long-term psychoanalytic psychotherapy (LTPP) was better than TAU alone in improving the long-term outcomes and reducing the risk of relapse. A previous blog on the original TADS study upon its publication, pointed out that a cost-effectiveness analysis could have been helpful to include to deliver a more realistic picture of the decision-making in psychological healthcare (McDonald, 2016). Koeser et al. (2023) have now released a new peer-reviewed paper utilising the TADS RCT data to compare the cost-effectiveness of LTPP and TAU together versus TAU alone.